Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We conducted an open-label, randomized clinical trial to assess parasite clearance times (PCT) and the efficacy of 4 mg/kg (group 1, n = 22) and 2 mg/kg (group 2, n = 22) of oral artesunate for three days followed by artemether-lumefantrine in patients with uncomplicated Plasmodium falciparum malaria at Xepon Interdistrict Hospital, Savannakhet Province in southern Laos. Slides were read in duplicate. The overall mean (95% confidence interval; range) PCT in hours was 23.2 (21.2-25.3; 12-46) and 22.4 (20.3-24.5; 12-46) for the first and second microscopists, respectively (P = 0.57). Ten (23%) patients remained parasitemic on day 1 after treatment (4 [18%] in group 1 and 6 [27%] in group 2; P = 0.47). No patient had patent asexual parasitemia on the second and third days of treatment. The 42-day polymerase chain reaction-corrected cure rates were 100% in both treatment groups. Serious adverse events did not develop during or after treatment in any patients. In conclusion, no evidence of P. falciparum in vivo resistance to artesunate was found in southern Laos.

Original publication

DOI

10.4269/ajtmh.2012.11-0497

Type

Journal article

Journal

Am J Trop Med Hyg

Publication Date

03/2012

Volume

86

Pages

403 - 408

Keywords

Administration, Oral, Adolescent, Adult, Aged, Antimalarials, Artemether, Lumefantrine Drug Combination, Artemisinins, Artesunate, Child, Drug Combinations, Drug Resistance, Drug Therapy, Combination, Ethanolamines, Female, Fluorenes, Follow-Up Studies, Humans, Laos, Malaria, Falciparum, Male, Middle Aged, Plasmodium falciparum, Treatment Outcome, Young Adult